Cargando…

Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study

BACKGROUND: A subset of patients with COVID-19 develops a hyperinflammatory syndrome that has similarities with other hyperinflammatory disorders. However, clinical criteria specifically to define COVID-19-associated hyperinflammatory syndrome (cHIS) have not been established. We aimed to develop an...

Descripción completa

Detalles Bibliográficos
Autores principales: Webb, Brandon J, Peltan, Ithan D, Jensen, Paul, Hoda, Daanish, Hunter, Bradley, Silver, Aaron, Starr, Nathan, Buckel, Whitney, Grisel, Nancy, Hummel, Erika, Snow, Gregory, Morris, Dave, Stenehjem, Eddie, Srivastava, Rajendu, Brown, Samuel M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524533/
https://www.ncbi.nlm.nih.gov/pubmed/33015645
http://dx.doi.org/10.1016/S2665-9913(20)30343-X
_version_ 1783588559980068864
author Webb, Brandon J
Peltan, Ithan D
Jensen, Paul
Hoda, Daanish
Hunter, Bradley
Silver, Aaron
Starr, Nathan
Buckel, Whitney
Grisel, Nancy
Hummel, Erika
Snow, Gregory
Morris, Dave
Stenehjem, Eddie
Srivastava, Rajendu
Brown, Samuel M
author_facet Webb, Brandon J
Peltan, Ithan D
Jensen, Paul
Hoda, Daanish
Hunter, Bradley
Silver, Aaron
Starr, Nathan
Buckel, Whitney
Grisel, Nancy
Hummel, Erika
Snow, Gregory
Morris, Dave
Stenehjem, Eddie
Srivastava, Rajendu
Brown, Samuel M
author_sort Webb, Brandon J
collection PubMed
description BACKGROUND: A subset of patients with COVID-19 develops a hyperinflammatory syndrome that has similarities with other hyperinflammatory disorders. However, clinical criteria specifically to define COVID-19-associated hyperinflammatory syndrome (cHIS) have not been established. We aimed to develop and validate diagnostic criteria for cHIS in a cohort of inpatients with COVID-19. METHODS: We searched for clinical research articles published between Jan 1, 1990, and Aug 20, 2020, on features and diagnostic criteria for secondary haemophagocytic lymphohistiocytosis, macrophage activation syndrome, macrophage activation-like syndrome of sepsis, cytokine release syndrome, and COVID-19. We compared published clinical data for COVID-19 with clinical features of other hyperinflammatory or cytokine storm syndromes. Based on a framework of conserved clinical characteristics, we developed a six-criterion additive scale for cHIS: fever, macrophage activation (hyperferritinaemia), haematological dysfunction (neutrophil to lymphocyte ratio), hepatic injury (lactate dehydrogenase or asparate aminotransferase), coagulopathy (D-dimer), and cytokinaemia (C-reactive protein, interleukin-6, or triglycerides). We then validated the association of the cHIS scale with in-hospital mortality and need for mechanical ventilation in consecutive patients in the Intermountain Prospective Observational COVID-19 (IPOC) registry who were admitted to hospital with PCR-confirmed COVID-19. We used a multistate model to estimate the temporal implications of cHIS. FINDINGS: We included 299 patients admitted to hospital with COVID-19 between March 13 and May 5, 2020, in analyses. Unadjusted discrimination of the maximum daily cHIS score was 0·81 (95% CI 0·74–0·88) for in-hospital mortality and 0·92 (0·88–0·96) for mechanical ventilation; these results remained significant in multivariable analysis (odds ratio 1·6 [95% CI 1·2–2·1], p=0·0020, for mortality and 4·3 [3·0–6·0], p<0·0001, for mechanical ventilation). 161 (54%) of 299 patients met two or more cHIS criteria during their hospital admission; these patients had higher risk of mortality than patients with a score of less than 2 (24 [15%] of 138 vs one [1%] of 161) and for mechanical ventilation (73 [45%] vs three [2%]). In the multistate model, using daily cHIS score as a time-dependent variable, the cHIS hazard ratio for worsening from low to moderate oxygen requirement was 1·4 (95% CI 1·2–1·6), from moderate oxygen to high-flow oxygen 2·2 (1·1–4·4), and to mechanical ventilation 4·0 (1·9–8·2). INTERPRETATION: We proposed and validated criteria for hyperinflammation in COVID-19. This hyperinflammatory state, cHIS, is commonly associated with progression to mechanical ventilation and death. External validation is needed. The cHIS scale might be helpful in defining target populations for trials and immunomodulatory therapies. FUNDING: Intermountain Research and Medical Foundation.
format Online
Article
Text
id pubmed-7524533
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-75245332020-09-30 Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study Webb, Brandon J Peltan, Ithan D Jensen, Paul Hoda, Daanish Hunter, Bradley Silver, Aaron Starr, Nathan Buckel, Whitney Grisel, Nancy Hummel, Erika Snow, Gregory Morris, Dave Stenehjem, Eddie Srivastava, Rajendu Brown, Samuel M Lancet Rheumatol Articles BACKGROUND: A subset of patients with COVID-19 develops a hyperinflammatory syndrome that has similarities with other hyperinflammatory disorders. However, clinical criteria specifically to define COVID-19-associated hyperinflammatory syndrome (cHIS) have not been established. We aimed to develop and validate diagnostic criteria for cHIS in a cohort of inpatients with COVID-19. METHODS: We searched for clinical research articles published between Jan 1, 1990, and Aug 20, 2020, on features and diagnostic criteria for secondary haemophagocytic lymphohistiocytosis, macrophage activation syndrome, macrophage activation-like syndrome of sepsis, cytokine release syndrome, and COVID-19. We compared published clinical data for COVID-19 with clinical features of other hyperinflammatory or cytokine storm syndromes. Based on a framework of conserved clinical characteristics, we developed a six-criterion additive scale for cHIS: fever, macrophage activation (hyperferritinaemia), haematological dysfunction (neutrophil to lymphocyte ratio), hepatic injury (lactate dehydrogenase or asparate aminotransferase), coagulopathy (D-dimer), and cytokinaemia (C-reactive protein, interleukin-6, or triglycerides). We then validated the association of the cHIS scale with in-hospital mortality and need for mechanical ventilation in consecutive patients in the Intermountain Prospective Observational COVID-19 (IPOC) registry who were admitted to hospital with PCR-confirmed COVID-19. We used a multistate model to estimate the temporal implications of cHIS. FINDINGS: We included 299 patients admitted to hospital with COVID-19 between March 13 and May 5, 2020, in analyses. Unadjusted discrimination of the maximum daily cHIS score was 0·81 (95% CI 0·74–0·88) for in-hospital mortality and 0·92 (0·88–0·96) for mechanical ventilation; these results remained significant in multivariable analysis (odds ratio 1·6 [95% CI 1·2–2·1], p=0·0020, for mortality and 4·3 [3·0–6·0], p<0·0001, for mechanical ventilation). 161 (54%) of 299 patients met two or more cHIS criteria during their hospital admission; these patients had higher risk of mortality than patients with a score of less than 2 (24 [15%] of 138 vs one [1%] of 161) and for mechanical ventilation (73 [45%] vs three [2%]). In the multistate model, using daily cHIS score as a time-dependent variable, the cHIS hazard ratio for worsening from low to moderate oxygen requirement was 1·4 (95% CI 1·2–1·6), from moderate oxygen to high-flow oxygen 2·2 (1·1–4·4), and to mechanical ventilation 4·0 (1·9–8·2). INTERPRETATION: We proposed and validated criteria for hyperinflammation in COVID-19. This hyperinflammatory state, cHIS, is commonly associated with progression to mechanical ventilation and death. External validation is needed. The cHIS scale might be helpful in defining target populations for trials and immunomodulatory therapies. FUNDING: Intermountain Research and Medical Foundation. Elsevier Ltd. 2020-12 2020-09-29 /pmc/articles/PMC7524533/ /pubmed/33015645 http://dx.doi.org/10.1016/S2665-9913(20)30343-X Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Articles
Webb, Brandon J
Peltan, Ithan D
Jensen, Paul
Hoda, Daanish
Hunter, Bradley
Silver, Aaron
Starr, Nathan
Buckel, Whitney
Grisel, Nancy
Hummel, Erika
Snow, Gregory
Morris, Dave
Stenehjem, Eddie
Srivastava, Rajendu
Brown, Samuel M
Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study
title Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study
title_full Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study
title_fullStr Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study
title_full_unstemmed Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study
title_short Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study
title_sort clinical criteria for covid-19-associated hyperinflammatory syndrome: a cohort study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524533/
https://www.ncbi.nlm.nih.gov/pubmed/33015645
http://dx.doi.org/10.1016/S2665-9913(20)30343-X
work_keys_str_mv AT webbbrandonj clinicalcriteriaforcovid19associatedhyperinflammatorysyndromeacohortstudy
AT peltanithand clinicalcriteriaforcovid19associatedhyperinflammatorysyndromeacohortstudy
AT jensenpaul clinicalcriteriaforcovid19associatedhyperinflammatorysyndromeacohortstudy
AT hodadaanish clinicalcriteriaforcovid19associatedhyperinflammatorysyndromeacohortstudy
AT hunterbradley clinicalcriteriaforcovid19associatedhyperinflammatorysyndromeacohortstudy
AT silveraaron clinicalcriteriaforcovid19associatedhyperinflammatorysyndromeacohortstudy
AT starrnathan clinicalcriteriaforcovid19associatedhyperinflammatorysyndromeacohortstudy
AT buckelwhitney clinicalcriteriaforcovid19associatedhyperinflammatorysyndromeacohortstudy
AT griselnancy clinicalcriteriaforcovid19associatedhyperinflammatorysyndromeacohortstudy
AT hummelerika clinicalcriteriaforcovid19associatedhyperinflammatorysyndromeacohortstudy
AT snowgregory clinicalcriteriaforcovid19associatedhyperinflammatorysyndromeacohortstudy
AT morrisdave clinicalcriteriaforcovid19associatedhyperinflammatorysyndromeacohortstudy
AT stenehjemeddie clinicalcriteriaforcovid19associatedhyperinflammatorysyndromeacohortstudy
AT srivastavarajendu clinicalcriteriaforcovid19associatedhyperinflammatorysyndromeacohortstudy
AT brownsamuelm clinicalcriteriaforcovid19associatedhyperinflammatorysyndromeacohortstudy